Figure 2.

Therapeutic regimen of ex vivo transfection of mRNA on dendritic cells (DCs). The utilization of DCs as a vaccination platform entails the transfection of DCs with mRNA encoding tumor antigens, followed by their delivery to the host, thereby triggering an immune response against the specific antigen. After successful ex vivo transfection of DCs with mRNA, these modified cells are re-infused into the recipient as an autologous vaccine, with the aim of eliciting immune responses. Consequently, most ex vivo-transfected DC vaccines predominantly foster a cell-mediated immune response, a valuable feature for the treatment of cancer.